Injectafer is a prescription intravenous iron infusion used to treat iron deficiency anemia in adults and children age 1 and older, as well as iron deficiency in adults with heart failure. It delivers iron directly into the bloodstream, bypassing the digestive system, which makes it an option when iron pills haven’t worked or aren’t tolerated.
FDA-Approved Uses
Injectafer (the brand name for ferric carboxymaltose) has three distinct approved uses. The first and most common is treating iron deficiency anemia in adults and pediatric patients 1 year and older who have tried oral iron supplements and either couldn’t tolerate them (due to stomach pain, nausea, or constipation) or didn’t see adequate improvement in their iron levels. The second is treating iron deficiency anemia in adults with non-dialysis dependent chronic kidney disease, regardless of whether they’ve tried oral iron first. The third, added more recently, is treating iron deficiency in adults with heart failure (NYHA class II or III) to improve exercise capacity.
These are the labeled indications, but the most frequent real-world scenario is straightforward: you have iron deficiency anemia, oral iron isn’t cutting it, and your provider recommends an infusion to replenish your stores more quickly and reliably.
Why IV Iron Instead of Pills
Oral iron supplements are the standard first step for iron deficiency, but they fail a significant number of people. Some can’t tolerate the gastrointestinal side effects. Others absorb iron poorly due to inflammatory bowel disease, celiac disease, or gastric bypass surgery. And in some cases, blood loss outpaces what oral supplements can replace, particularly with heavy menstrual periods or chronic GI bleeding.
Injectafer sidesteps all of these problems by delivering iron directly into the bloodstream. Because the iron goes straight into circulation, the body can use it to produce new red blood cells without relying on gut absorption. This also means results tend to come faster. Most people notice improvements in energy and fatigue within a few weeks of completing their infusion course, though full replenishment of iron stores can take longer.
Iron Deficiency With Heart Failure
Iron deficiency is remarkably common in people with heart failure, even when they aren’t technically anemic. Low iron worsens fatigue and exercise intolerance in these patients, compounding the limitations heart failure already imposes. The FDA approved Injectafer specifically for heart failure patients with NYHA class II or III symptoms, meaning those with mild to moderate physical limitations from their condition.
The approval was based on a clinical trial (CONFIRM-HF) that enrolled patients with chronic heart failure, reduced heart function (ejection fraction below 45%), and confirmed iron deficiency. After 24 weeks, patients who received Injectafer could walk farther in a six-minute walk test compared to those who received a placebo. This is a meaningful real-world outcome: it translates to being able to do more daily activity with less exhaustion.
Chronic Kidney Disease
The kidneys play a key role in red blood cell production by making a hormone that signals your bone marrow to produce more cells. When kidney function declines, this signal weakens, and iron deficiency becomes both more common and harder to correct with oral supplements. Injectafer is approved for adults with chronic kidney disease who are not on dialysis. Patients already receiving dialysis typically get a different form of IV iron during their dialysis sessions.
What the Infusion Looks Like
For adults weighing 110 pounds (50 kg) or more, the standard regimen is two infusions of 750 mg each, given at least 7 days apart, for a total of 1,500 mg of iron per treatment course. There’s also a single-dose option: up to 1,000 mg given in one visit. For those weighing under 110 pounds, dosing is based on body weight at 15 mg per kilogram, split into two sessions at least 7 days apart.
Each infusion is given through an IV, either as a slow push or a short drip, and typically takes about 15 to 30 minutes. You’ll usually be monitored for a brief period afterward. Many people complete the entire treatment course in just one or two visits, which is a notable advantage over some older IV iron formulations that required more frequent sessions.
Side Effects to Know About
The most common side effects are mild: headache, nausea, dizziness, flushing, and a temporary change in skin color at the injection site. These tend to resolve within a day or two.
One side effect that deserves specific attention is low phosphorus levels (hypophosphatemia). In a randomized trial comparing Injectafer to another IV iron product, about 51% of Injectafer patients developed low phosphorus, compared to less than 1% of patients receiving the alternative. Most cases are mild and temporary, but severe or prolonged drops in phosphorus can cause muscle weakness, bone pain, and fatigue. This is something your provider should monitor with blood work, particularly if you need repeat treatment courses. The risk appears to be higher with repeated infusions over time.
Serious allergic reactions are possible but rare. Because of this risk, Injectafer is given in a medical setting where staff can respond quickly if a reaction occurs.
Who Shouldn’t Get Injectafer
Injectafer is not appropriate for people with iron overload conditions, such as hemochromatosis, since adding more iron would be harmful. It’s also not for anyone who has had a serious allergic reaction to Injectafer or any of its ingredients in the past. Your provider will check your iron levels before and after treatment to confirm that iron deficiency is genuinely the problem and that the infusion is having the intended effect.